Aethon Therapeutics

About Aethon Therapeutics

The startup develops a cancer immunotherapy platform that designs neoantigens to enhance targeted therapies against oncogenic driver mutations, including RAS and EGFR. This approach aims to effectively eliminate residual cancer cells, including drug-resistant persister cells, improving treatment outcomes for patients with cancer.

What does Aethon Therapeutics do?

The startup develops a cancer immunotherapy platform that designs neoantigens to enhance targeted therapies against oncogenic driver mutations, including RAS and EGFR. This approach aims to effectively eliminate residual cancer cells, including drug-resistant persister cells, improving treatment outcomes for patients with cancer.

Where is Aethon Therapeutics located?

Aethon Therapeutics is based in City of New York, United States.

When was Aethon Therapeutics founded?

Aethon Therapeutics was founded in 2022.

How much funding has Aethon Therapeutics raised?

Aethon Therapeutics has raised 30000000.

Location
City of New York, United States
Founded
2022
Funding
30000000
Employees
14 employees
Looking for specific startups?
Try our free semantic startup search

Aethon Therapeutics

Score: 100/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

The startup develops a cancer immunotherapy platform that designs neoantigens to enhance targeted therapies against oncogenic driver mutations, including RAS and EGFR. This approach aims to effectively eliminate residual cancer cells, including drug-resistant persister cells, improving treatment outcomes for patients with cancer.

aethontx.com1K+
cb
Crunchbase
Founded 2022City of New York, United States

Funding

$

Estimated Funding

$30M+

Team (10+)

Christoph Rader

CTO

Aethon Therapeutics - Funding: $30M+ | StartupSeeker